Advanced search
1 file | 655.16 KB Add to list

Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia : a multinational point prevalence study of hospitalised patients

Author
Organization
Abstract
Pseudornonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.
Keywords
CARE-ASSOCIATED PNEUMONIA, MULTIDRUG-RESISTANT PATHOGENS, INFECTIOUS-DISEASES-SOCIETY, GRAM-NEGATIVE BACTERIA, ANTIBIOTIC-THERAPY, THORACIC-SOCIETY, GUIDELINES, ADULTS, ENTEROBACTERIACEAE, EPIDEMIOLOGY

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 655.16 KB

Citation

Please use this url to cite or link to this publication:

MLA
Restrepo, Marcos, I et al. “Burden and Risk Factors for Pseudomonas Aeruginosa Community-acquired Pneumonia : a Multinational Point Prevalence Study of Hospitalised Patients.” EUROPEAN RESPIRATORY JOURNAL 52.2 (2018): n. pag. Print.
APA
Restrepo, M., I., Babu, B. L., Reyes, L. F., Chalmers, J. D., Soni, N. J., Sibila, O., Faverio, P., et al. (2018). Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia : a multinational point prevalence study of hospitalised patients. EUROPEAN RESPIRATORY JOURNAL, 52(2).
Chicago author-date
Restrepo, Marcos, I, Bettina L Babu, Luis F Reyes, James D Chalmers, Nilam J Soni, Oriol Sibila, Paola Faverio, et al. 2018. “Burden and Risk Factors for Pseudomonas Aeruginosa Community-acquired Pneumonia : a Multinational Point Prevalence Study of Hospitalised Patients.” European Respiratory Journal 52 (2).
Chicago author-date (all authors)
Restrepo, Marcos, I, Bettina L Babu, Luis F Reyes, James D Chalmers, Nilam J Soni, Oriol Sibila, Paola Faverio, Catia Cilloniz, William Rodriguez-Cintron, Stefano Aliberti, the GLIMP investigators, and Eva Van Braeckel. 2018. “Burden and Risk Factors for Pseudomonas Aeruginosa Community-acquired Pneumonia : a Multinational Point Prevalence Study of Hospitalised Patients.” European Respiratory Journal 52 (2).
Vancouver
1.
Restrepo M I, Babu BL, Reyes LF, Chalmers JD, Soni NJ, Sibila O, et al. Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia : a multinational point prevalence study of hospitalised patients. EUROPEAN RESPIRATORY JOURNAL. 2018;52(2).
IEEE
[1]
M. Restrepo I. et al., “Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia : a multinational point prevalence study of hospitalised patients,” EUROPEAN RESPIRATORY JOURNAL, vol. 52, no. 2, 2018.
@article{8603565,
  abstract     = {Pseudornonas aeruginosa is a challenging bacterium to treat due to its intrinsic resistance to the antibiotics used most frequently in patients with community-acquired pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-CAP are limited. We assessed the multinational burden and specific risk factors associated with P. aeruginosa-CAP. 
We enrolled 3193 patients in 54 countries with confirmed diagnosis of CAP who underwent microbiological testing at admission. Prevalence was calculated according to the identification of P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-susceptible and antibiotic-resistant P. aeruginosa-CAP. 
The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonisation due to P. aeruginosa and at least one of the three independently associated chronic lung diseases (i.e. tracheostomy, bronchiectasis and/or very severe chronic obstructive pulmonary disease) was 67%. In contrast, the rate of P. aeruginosa-CAP was 2% in patients without prior P. aeruginosa infection/colonisation and none of the selected chronic lung diseases. The multinational prevalence of P. aeruginosa-CAP is low. 
The risk factors identified in this study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP patients.},
  articleno    = {1701190},
  author       = {Restrepo, Marcos, I and Babu, Bettina L and Reyes, Luis F and Chalmers, James D and Soni, Nilam J and Sibila, Oriol and Faverio, Paola and Cilloniz, Catia and Rodriguez-Cintron, William and Aliberti, Stefano and GLIMP investigators, the and Van Braeckel, Eva},
  issn         = {0903-1936},
  journal      = {EUROPEAN RESPIRATORY JOURNAL},
  keywords     = {CARE-ASSOCIATED PNEUMONIA,MULTIDRUG-RESISTANT PATHOGENS,INFECTIOUS-DISEASES-SOCIETY,GRAM-NEGATIVE BACTERIA,ANTIBIOTIC-THERAPY,THORACIC-SOCIETY,GUIDELINES,ADULTS,ENTEROBACTERIACEAE,EPIDEMIOLOGY},
  language     = {eng},
  number       = {2},
  pages        = {14},
  title        = {Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia : a multinational point prevalence study of hospitalised patients},
  url          = {http://dx.doi.org/10.1183/13993003.01190-2017},
  volume       = {52},
  year         = {2018},
}

Altmetric
View in Altmetric
Web of Science
Times cited: